http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PE-20040836-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-073 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-067 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-073 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7052 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7072 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068 |
| filingDate | 2003-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34b3b726069d5c825aa3a8fc2bcaf154 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b3e7344503a143cc35255511628d4e2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ef2534d6dd0bb71ab73bf8f858c75f9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de36567ec8dd8ceb445f811a3932c28b |
| publicationDate | 2004-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | PE-20040836-A1 |
| titleOfInvention | PYRIMIDINE NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HEPATITIS C VIRUS RNA REPLICATION (HCV) |
| abstract | REFERS TO PYRIMIDINE NUCLEOSIDE DERIVATIVES OF FORMULA I, WHERE R1 AND R2 ARE H, COR5, C (= O) OR5, C (= O) SR5, AMONG OTHERS; R3 AND R4 ARE H, COR5, C (= O) OR5, C (= O) SR5, AMONG OTHERS; OR R3 AND R4 TAKEN TOGETHER ARE CH2, C (CH3) 2, or CHPh; R5 IS C1-C18 ALKYL BRANCHED OR NOT, C1-C18 ALKENYL BRANCHED OR NOT, C1-C18 ALKYL BRANCHED OR NOT, C1-C18 HALOALKYL, AMONG OTHERS; WITH THE CONDITION THAT AT LEAST ONE OF R1, R2, R3 or R4 IS OTHER THAN HYDROGEN. THESE COMPOUNDS MAY BE PRESENT IN THE FORM OF HYDRATES, SOLVATES, CLATRATES AND ACID ADDITION SALTS. PREFERRED COMPOUNDS ARE: (2R, 3S, 4R, 5R) -3,4-DIACETOXY-5- (4-ACETHYLAMINE-2-OXO-2H-PYRIMIDIN-1-IL) -2-AZIDO-TETRAHYDRO-FURAN- ACETATE. 2-ILMETHYL; (2R, 3S, 4R, 5R) -2-AZIDO-5- (2-OXO-4-PROPIONYLAMINE-2H-PYRIMIDIN-1-IL) -3,4-BIS-PROPIONYLOXY-TETRAHYDRO-FURAN-2- PROPIONATE ILMETHYL; (2R, 3S, 4R, 5R) -2-AZIDO-5- (4-BUTYRILAMINE-2-OXO-2H-PYRIMIDIN-1-IL) -3,4-BIS-BUTYRILOXY-TETRAHYDRO-FURAN-2- BUTYRATE ILMETHYL; AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION AND A PROCESS FOR THE PREPARATION OF A 1 ', 3', 4'-TRIACIL PYRIMIDINE NUCLEOSIDE FROM A N, 1 ', 3', 4'-TETRAACILPYRIMIDINE NUCLEOSIDE. THESE COMPOUNDS ARE INHIBITORS OF RNA REPLICATION OF THE REPLICON HEPATIS C VIRUS AND ARE USEFUL TO TREAT DISEASES MEDIATED BY THE HEPATITIS C VIRUS |
| priorityDate | 2002-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415966410 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID439920 |
Total number of triples: 28.